Alexandra Drebka

Mrs. Alexandra Drebka

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2026 in Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
ADAlexandra Drebka
Alexandra Drebka
ASAnnika Johanna Scholl
Annika Johanna Scholl
CJChristian O. Jacke
Christian O. Jacke
BBBeatrice Elisabeth Bachmeier
Beatrice Elisabeth Bachmeier
Background: Menstrual and menopausal complaints are highly prevalent among women in Germany. Pharmacological options include hormonal contraceptives, menopausal hormone therapy and herbal medicinal products (HMPs). However, real-world data on the prescription of HMPs in comparison with hormone preparations are scarce. Objective: To describe trends in the number and proportion of packages of hormone preparations and HMPs within ATC groups with pharmacotherapeutic relevance to menstrual and menopausal complaints, using claims data from German private health insurance (PHI). As no diagnoses were available, the study does not address the indications for which the products were prescribed. Design: Repeated cross-sectional observational study. Methods: Claims data were derived from the drug project of the Scientific Institute of Private Health Insurance (WIP), including all packages dispensed to women aged ≥12 years from 2019 to 2022 within the ATC groups G03A, G03C, G03F or G02CP. In total, 2.8 million drug packages were analysed using descriptive methods and exploratory quasi-binomial regression models. Key Results: Hormone preparations (G03) accounted for 91.5% of all packages, compared with 8.5% for gynaecological HMPs (G02). Following an initial decline until 2021, the number of hormone packages nearly returned to the level in 2019, whereas the number of HMP packages showed a continuous downward trend. Among menstruation-related preparations dispensed to younger women (aged 12–25 years), hormonal contraceptives (G03A) accounted for the vast majority (92.2%). The proportion of HMP packages (G02CP01, -02, -05, -07, -08) increased steadily with age, exceeding the proportion of G03A packages among women aged over 60 years (59.2% vs. 40.8%). Among menopause-related preparations, hormone packages (G03C, G03F) predominated across all age groups (>90%) and HMP packages (G02CP03, -04, -53) accounted for less than 10%. Conclusions: Among privately insured women in Germany, hormone preparations accounted for most packages in both medication groups, whereas HMPs accounted for a small and declining share that increased with age only in the menstruation-related group. PHI claims data can complement statutory health insurance data, as they also capture prescribed non-prescription drugs such as HMPs.

29 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ADAlexandra Drebka
Alexandra Drebka
ASAnnika Johanna Scholl
Annika Johanna Scholl
CJChristian O Jacke
Christian O Jacke
BBBeatrice Elisabeth Bachmeier
Beatrice Elisabeth Bachmeier
Background Despite established pharmacological treatments, menstrual and climacteric complaints remain highly prevalent among women in Germany, suggesting that conventional therapies - hormonal contraceptives and hormone replacement therapy - may not fully meet patients’ needs. However, real-world data on the prescription of herbal medicinal products are scarce. Objective To analyze utilization patterns of synthetic therapies and HMPs in real-world gynecological care. Design Repeated cross-sectional observational study. Methods Prescription data were derived from the drug project of the Scientific Institute of Private Health Insurance (WIP), including all prescriptions from 2019 to 2022 for menstrual or climacteric complaints assigned to ATC codes G03A, G03C, G03F or G02CP. Persons under 12 years of age were excluded. In total, 2.8 million prescriptions were analyzed using resource-oriented methodological approaches and descriptive statistics. Key Results Hormone Preparations (G03) accounted for 91.5% of all prescriptions, while gynecological HMPs (G02) represented only 8.5%. Following an initial decline until 2021, the use of hormones nearly returned to baseline, whereas prescriptions of HMPs showed a continuous downward trend. Among women aged 12-25 years, HCs (G03A) predominated (92.2%), with HMPs (G02CP-01; -02; -05; -07) accounting for 7.8%. The proportion of HMPs increased steadily with age and surpassed synthetic hormonal preparations among women aged over 60 years (59.1% vs. 40.8%). For climacteric ailments, HRT medications (G03C, G03F) were predominant across all age groups (>90%), whereas HMPs (G02CP-03; -04; -53) remained below 10%, peaking among women aged 41-65 years (8.8%).

6 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAnnika Johanna Scholl
Annika Johanna Scholl
ADAlexandra Drebka
Alexandra Drebka
JKJulie Kristin Könnecke
Julie Kristin Könnecke
NBNele Liesbeth Bößneck
Nele Liesbeth Bößneck
AHAlexander Hau
Alexander Hau
BBBeatrice Elisabeth Bachmeier
Beatrice Elisabeth Bachmeier
Background: Patients taking multiple medications are at particular risk of cognitive impairment, especially when anticholinergic drugs are involved. Standardised Ginkgo biloba L. leaf extracts (GBE) are a well-established treatment option for cognitive symptoms, but evidence on GBE in combination with concomitant medication remains limited. In this study, we investigated patient-reported outcomes from the pharmacoepidemiologic database PhytoVIS regarding GBE utilization for cognitive impairment in relation to co-medication. Methods: In a study cohort of 191 patients, we examined associations between co-medication and treatment patterns, perceived effectiveness and tolerability of GBE using descriptive statistics and non-parametric bivariate analyses. Anticholinergic burden was assessed using the German Anticholinergic Burden Scale (GABS). Retrospective case reports were prepared for all patients with significant adverse events (SAE) and patients with critical GABS scores. Results: Overall, 64.9% of patients used co-medication, most commonly cardiovascular drugs (47.5%), antidiabetic and analgesics/anti-inflammatory drugs (8.8% each). While there was no association with treatment duration or intake frequency, a higher number of co-medications was linked to lower GBE doses (p=0.03). Three patients reported SAEs during GBE intake, however overall perceived effectiveness and tolerability of GBE remained high irrespective of co-medication. Four GBE users had critical GABS scores (>2); all reported remission of cognitive symptoms. Conclusion: Although more co-medications were associated with lower GBE doses, perceived effectiveness and tolerability remained favourable. However, the findings highlight the importance of monitoring herbal medicinal products in self-medication, particularly in patients with co-medication, while also suggesting that GBE may support the management of cognitive impairment associated with anticholinergic therapies.